Arno Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Cost of Goods Sold (COGS) incl. D&A
11.70
13.80
13.10
12.60
7.60
Gross Income
11.70
13.80
13.10
12.60
7.60
SG&A Expense
7,635.30
10,822.00
16,927.40
21,480.70
13,404.20
EBIT
7,647.00
10,835.80
16,940.60
21,493.30
13,411.80
Unusual Expense
-
-
-
29,193.40
1,920.80
Non Operating Income/Expense
290.90
3,559.80
4,165.00
28.90
3,845.40
Interest Expense
-
-
18,569.20
0.10
28.40
Pretax Income
7,909.10
14,387.80
39,657.00
7,770.80
11,508.00
Consolidated Net Income
7,909.10
14,387.80
39,657.00
7,770.80
11,508.00
Net Income
7,909.10
14,387.80
39,657.00
7,770.80
11,508.00
Net Income After Extraordinaries
7,909.10
14,387.80
39,657.00
7,770.80
11,508.00
Net Income Available to Common
7,990.80
14,387.80
39,657.00
7,770.80
11,508.00
EPS (Basic)
1.84
3.17
5.28
0.31
0.56
Basic Shares Outstanding
4,314.30
4,540.30
7,516.20
20,381.60
20,408.60
EPS (Diluted)
1.85
3.17
5.28
0.31
0.56
Diluted Shares Outstanding
4,314.30
4,540.30
7,516.20
24,810.00
20,408.60
EBITDA
7,635.30
10,822.00
16,927.40
21,480.70
13,404.20
Non-Operating Interest Income
28.80
7.80
17.70
42.00
7.70
Preferred Dividends
81.70
-
-
-
-
About Arno Therapeutics
View Profile
